Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber

Murdoch, Robert D., Bareille, Philippe, Ignar, Diane, Mark, Stephen, Miller, Sam R., Gupta, Ashutosh, Salapatek, Anne-Marie, Patel, Piyush · 2015 · Int. Journal of Clinical Pharmacology and Therapeutics

Abstract

OBJECTIVES: To test the hypothesis that intranasal levocabastine (LEVO) may provide benefits as a oncedaily treatment in allergic rhinitis (AR), this non-inferiority study compared the effect at steady state of once- and twice-daily dosing with LEVO on allergen-induced nasal symptoms in AR patients. METHODS: This was a randomized, double-blind, three-way cross over study evaluating the effects of repeat doses of LEVO 200 µg once-daily, LEVO 200 µg twice-daily (total dose 400 µg) and placebo, all via intranasal spray, in 78 AR patients. The primary endpoint was weighted mean total nasal symptom score (TNSS) during a 4-hour allergen exposure in the Environmental Exposure Chamber measured at trough pharmacokinetic levels either 12 (LEVO twice-daily) or 24 (LEVO once-daily) hours post-dose. RESULTS: After 7 days dosing, the difference in weighted mean TNSS (0-4 hours) following LEVO once-daily versus twice-daily was 0.23 units (95% CI -0.36, 0.82), demonstrating noninferiority between the two LEVO dosing regimens by meeting the pre-specified criterion of an upper limit of 95% CI<1.0. Both dosing regimens of LEVO resulted in a statistically significant reduction in mean TNSS compared with placebo (adjusted mean difference from placebo: LEVO once-daily: -1.12 (95% CI -1.71, -0.53); LEVO twice-daily: -1.35 (-1.94, -0.76)), meeting the pre-specified criterion for superiority (upper limit of 95% CI<0). All treatments were well-tolerated. CONCLUSIONS: The results of this study support the hypothesis that at steady state LEVO 200 µg taken once-daily provides similar benefit to LEVO 200 µg dosed twice-daily.

Overview

Integrity signals

Registry

Crossref · 10.5414/cp202389

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 6

Metadata

Authors
Murdoch, R. D., Bareille, P., Ignar, D., Mark, S., Miller, S. R., Gupta, A., Salapatek, A.-M., & Patel, P.
Venue
Int. Journal of Clinical Pharmacology and Therapeutics
Published
2015-10-01
Volume
53
Issue
10
Pages
811-818
ISSN
0946-1965 (ISSN-L)
OpenAlex
W2473809525
Cited by
6
References
0
Citations by year
2023: 1 · 2020: 1 · 2018: 1 · 2017: 2 · 2016: 1
FWCI
1.18
Type
journal article
Language
en
Open access
closed
Locations
  • International Journal of Clinical Pharmacology and Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
Keywords
levocabastine, allergic rhinitis, once-daily dosing, twice-daily dosing, dosing regimen comparison, nasal spray, allergen challenge, nasal symptom score, non-inferiority, steady-state pharmacokinetics, antihistamines
MeSH terms
Adult, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Piperidines, Cross-Over Studies, Histamine H1 Antagonists, Non-Sedating, Young Adult, Rhinitis, Allergic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber. https://app.cochat.ai/papers/10.5414/cp202389
The paper
Murdoch, R. D., Bareille, P., Ignar, D., Mark, S., Miller, S. R., Gupta, A., Salapatek, A.-M., & Patel, P. (2015). Once-daily dosing of levocabastine has comparable efficacy to twice-daily dosing in the treatment of allergic rhinitis assessed in an allergen challenge chamber. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp202389

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.